Influence of the American ODAC Statement on Austrian Bevacizumab Prescribing Practice for Metastatic Breast Cancer

BACKGROUND. Results of trial E2100 led to the accelerated approval of bevacizumab as first-line therapy for patients with metastatic breast cancer (MBC) in the U.S. in February 2008. Based on results from subsequent trials, the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee (OD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Preusser, Matthias, Fülöp, Gerhard, Berghoff, Anna Sophie, Heinzl, Harald, Steger, Guenther G., Greil, Richard, Zielinski, Christoph C., Bartsch, Rupert
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2012
Assuntos:
European Perspectives
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399659/
https://ncbi.nlm.nih.gov/pubmed/22744818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0115
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados